GeneDx Holdings (WGS) Liabilities and Shareholders Equity (2020 - 2026)

GeneDx Holdings (WGS) has reported Liabilities and Shareholders Equity for 7 consecutive years, with $481.5 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Liabilities and Shareholders Equity rose 3.8% year-over-year to $481.5 million in Q2 2026; TTM through Jun 2026 was $2.0 billion, a 15.35% increase from a year earlier, with the FY2025 full-year figure at $523.7 million, up 24.88% from the prior year.
• Liabilities and Shareholders Equity was $481.5 million for Q2 2026 at GeneDx Holdings, down from $506.3 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $933.3 million in Q2 2022 and troughed at $389.1 million in Q2 2024.
• A 5-year average of $508.7 million and a median of $478.9 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity surged 431.68% in 2022 and sank 49.66% in 2023, its largest moves.
• Over 5 years, Liabilities and Shareholders Equity stood at $490.9 million in 2022, then fell by 14.7% to $418.8 million in 2023, then climbed by 0.15% to $419.4 million in 2024, then grew by 24.88% to $523.7 million in 2025, then decreased by 8.06% to $481.5 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $481.5 million (Q2 2026), $506.3 million (Q1 2026), and $523.7 million (Q4 2025), per Business Quant data.